ONKT102 / ONK Therap, Vanderbilt University Medical Center - LARVOL DELTA

European Patent Office Grants ONK Therapeutics’ Foundational Patent for CISH Knockout in NK Cells for Use in Cancer Therapies (GlobeNewswire) - "ONK Therapeutics Ltd...today announced that the European Patent Office (EPO) has granted its licensed patent covering CISH knockout (KO) in NK cells, irrespective of the source of the NK cells, including human cord blood-derived, peripheral blood-derived, and NK cells derived from induced pluripotent stem cells (iPSCs)....The patent granted by EPO specifically covers CISH KO NK cells per se, and cancer therapies that utilize NK cells with CISH KO as well as NK cells engineered with the foundational CISH KO in combination with IL-15 (soluble or engineered), TGFβR2 KO, or TGFβR2 KO and IL-15 (soluble or engineered)."

Patent • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

ONK Therapeutics Presents Promising In-Vivo Data of its Optimized Affinity CD38 CAR-NK Candidate, Being Developed for the Treatment of Multiple Myeloma (Businesswire) - "ONK Therapeutics...announced the first in-vivo data for ONKT102, a fully human, optimized affinity CD38 CAR-NK cell therapy....The anti-tumor efficacy of the optimized CD38 CAR-NK cells was then evaluated in NOD scid gamma (NSG) mice inoculated with MM.1S-LUC cells. Mice underwent weekly bioluminescient imaging to monitor tumor burden. The results showed that CD38 CAR-NK cells significantly reduced tumor burden and improved survival versus control CB NK cells and vehicle control....'These results suggest that non-virally engineered, optimized affinity CD38 CAR-NK CD38 KO cells have potent anti-tumor activity in-vitro and in-vivo in a CD38 positive tumor model'."

Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology

ONK Therapeutics Announces $21.5M Series A Financing to Advance Pipeline of Next-Generation Optimally Engineered Off-the-Shelf NK Cell Therapies (Businesswire) - "ONK Therapeutics...announced the closing of its $21.5 million Series A financing, led by current investors Acorn Bioventures and ALSHC, who were joined by Cormorant Asset Management....The financing will enable ONK to maintain its strong momentum as it advances pre-clinical programs through comprehensive IND-enabling studies, including in-vivo proof-of-concept models across multiple programs."

Financing • Acute Myelogenous Leukemia • Breast Cancer • Gynecologic Cancers • Hematological Malignancies • Leukemia • Lung Cancer • Multiple Myeloma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor